

This material is an English translation of the press release announced on May 24, 2019 in Japanese, and the Japanese release is given priority about the content and the interpretation.

---

May 24, 2019

**Notification of the results of the Phase II clinical study of HP-5070 in Japan  
(a transdermal drug for the treatment of primary local hyperhidrosis)**

Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu city, Saga Prefecture, Japan; President and CEO: Kazuhide Nakatomi, hereinafter referred to as Hisamitsu) announces that it has results of the Phase II clinical study for “primary local hyperhidrosis” in Japan (Development code: HP-5070, hereinafter referred to as “the investigational product”).

In the Phase II clinical study, the efficacy and safety of administration of the investigational product had been compared with a placebo in patients with primary local hyperhidrosis. As a result, there was a statistically significant difference in the primary endpoint when compared the investigational product group with the placebo group. In addition, there were no adverse reactions that could cause major concerns in development.

In the future, Hisamitsu aims to initiate a Phase III clinical study during FY 2020.